Form 4: Director Timothy Still Buys VNRX Shares & Warrants

VOLITIONRX LTD Director Timothy Still acquired 48,076 common shares and an equal number of warrants in a public offering.

Summary

• Timothy I. Still, a Director of VOLITIONRX LTD (VNRX), purchased common stock and accompanying warrants.
• The transaction occurred on October 14, 2025, as part of an underwritten public offering by the Issuer.
• Mr. Still acquired 48,076 shares of common stock at a price of $0.51 per share.
• He also acquired 48,076 common stock warrants, each with an exercise price of $0.6 and an allocated price of $0.01.
• The reported sale price for the common stock and accompanying warrant was $0.52 per unit.
• Following these transactions, Mr. Still beneficially owns 1,535,458 shares of common stock and 48,076 warrants.

Sentiment

Score: 7

Explanation: The director's purchase of shares and warrants in a public offering indicates a positive sentiment and confidence in the company's future, which is generally viewed favorably by investors.

Positives

• Director Timothy I. Still purchased 48,076 shares of common stock and an equal number of warrants, indicating confidence in the company's future prospects.
• The purchase was made in connection with an underwritten public offering, suggesting participation in a broader capital raise.

Negatives

• No explicit negatives are reported in this Form 4 filing, which primarily details an insider transaction.

Risks

• No specific risks are mentioned in this Form 4 filing.

Future Outlook

This Form 4 filing does not contain specific forward-looking statements or guidance, as it primarily reports a completed insider transaction.

Management Comments

• While no direct quotes are provided, the act of a director purchasing shares in a public offering can be interpreted as a strong vote of confidence in the company's valuation and future prospects.

Industry Context

Insider purchases, especially by a director, are often viewed by the market as a positive signal, suggesting that those closest to the company believe its shares are undervalued or that significant positive developments are anticipated. This transaction occurred in connection with a public offering, which is a common method for companies to raise capital.

Comparison to Industry Standards

• This filing reports an insider transaction, which is a standard disclosure requirement. The specific details of the public offering (e.g., pricing, size) would typically be compared to similar offerings by companies in the biotechnology or diagnostics sector, but this Form 4 does not provide enough detail for such a comparison.

Related Party Transactions

• Timothy I. Still, a Director of VOLITIONRX LTD, purchased common stock and warrants from the underwriter in connection with a public offering by the Issuer. This constitutes a related party transaction due to his position as a director.

Stakeholder Impact

• Shareholders: May view the director's purchase as a positive signal, potentially increasing investor confidence and demand for the stock.
• Company: The public offering itself provides capital to the company, which can be used for operations, research, or strategic initiatives.

Next Steps

• No specific future actions or milestones are mentioned in this Form 4 filing.

Key Dates

Recommendation

The director's purchase of shares and warrants is a positive signal, indicating insider confidence in the company's prospects. However, without further financial context from the public offering itself or the company's broader performance, a single insider transaction typically warrants a 'hold' recommendation rather than a 'strong buy' for a seasoned investor, as it's one data point among many.

Keywords

VOLITIONRX, VNRX, Timothy Still, Insider Buying, Form 4, Common Stock, Warrants, Public Offering, Director Purchase, Equity Securities